Show simple item record

dc.contributorN/A, N/A
dc.contributor.authorMontes, Raul Caballero
dc.date.accessioned2022-09-22T20:56:48Z
dc.date.available2022-09-22T20:56:48Z
dc.date.issued2022-04-14
dc.identifier.urihttps://hdl.handle.net/10657/11745
dc.description.abstractAdoptive cell therapy using chimeric antigen receptor (CAR)-T cells represents a promising approach for human cancer immunotherapy. In this study, we examine the role of a MAP3K in mediating CAR-T cell function by generating CAR-T cells expressing a stable form of MAP3K lacking its N-terminal region (MAP3KK Delta N). We hypothesize that MAP3K Delta N expression will promote CAR-T cell activation and metabolic fitness in the tumor microenvironment. Using molecular cloning, a retroviral vector encoding a human CD19(hCD19)-specific CAR and mouse MAP3KK Delta N was constructed and confirmed by DNA sequencing. CD8+ T cells were isolated from C57BL/6 mice, activated in vitro, and then transduced with the hCD19-CAR-MAP3K Delta N vector. For functional analysis, B16-hCD19 tumor-bearing mice were injected with CAR-T cells expressing either wildtype MAP3K (MAP3K-WT) or MAP3KK Delta N, and tumor growth was monitored. Expression of MAP3K-WT improved the tumor-suppression function of hCD19-CAR-T cells. Surprisingly, CAR-T cells expressing MAP3KK Delta N displayed a lower antitumor efficacy than those expressing MAP3K-WT. Furthermore, these results were correlated in vitro, where MAP3KK Delta N showed a response similar to control CAR and reduced tumor inhibition in comparison with MAP3K-WT. Expression of MAP3K-WT, but not MAP3KK Delta N, profoundly improves the antitumor function of CAR-T cells. It is possible that MAP3KK Delta N expression results in T cell overactivation, thereby promoting T cell exhaustion and activation-induced cell death. These results suggest that optimal, rather than excessive, T cell activation is critical for potential therapeutic applications using MAP3K expression. However, it is also possible that deletion of the N-terminal portion of MAP3K impairs its facilitation of T cell metabolic functions.
dc.language.isoen_US
dc.titleManipulation of MAP3K Signaling to Improve CAR-T Cell Therapy
dc.typePoster
dc.description.departmentBiology and Biochemistry, Department of
dc.description.departmentHonors College


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record